Skip to content
Taxonomy
CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
From Gene Discovery to Gene Editing: Closing the Diagnostic Gap and Developing CRISPR/Cas9 Capabilities in CMT
Finding Your Gene Researchers have discovered over 120 genes linked Read More
2024 CMTA Patient & Research Summit Registration is Now Open
The 2024 CMTA Patient & Research Summit will take place Read More
CMTA Announces New Center of Excellence in the United Kingdom
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Read More
New Law Makes Flying Easier for People Living With Charcot-Marie-Tooth Disease
A partnership between the Charcot-Marie-Tooth Association (CMTA), Muscular Dystrophy Association Read More
CMTA Appoints Science and Technology Veteran, Patricia Verduin, PhD, to the Board of Directors
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
TAKE ACTION! Sign the Petition to Accelerate CMT-SORD
What is CMT-SORD? In 2019, with Charcot-Marie-Tooth Association (CMTA) funding, Read More
CMTA Announces Addition of Health Insurance Industry Veteran Wendy Arnone to the Board of Directors
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
CMTA Alliance Partner, NMD Pharma, Announces Encouraging Data with Implications for CMT
Charcot-Marie-Tooth Association (CMTA) Alliance Partner, NMD Pharma, announced the publication Read More
